FRM
MCRB icon

Fox Run Management’s Seres Therapeutics MCRB Stock Holding History

Fox Run Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-822
Closed -$93.3K – 854
2023
Q1 		$93.3K Buy
+822
New +$88.9K 0.03% 602
2022
Q1 		– Sell
-679
Closed -$113K – 626
2021
Q4 		$113K Buy
+679
New +$108K 0.07% 412
2017
Q2 		– Sell
-605
Closed -$136K – 741
2017
Q1 		$136K Buy
+605
New +$123K 0.06% 529
2016
Q4 		– Sell
-1,045
Closed -$257K – 603
2016
Q3 		$257K Buy
+1,045
New +$367K 0.15% 313

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Fox Run Management's MCRB Position: Q2 2023 in Review

Fox Run Management sold out of Seres Therapeutics (MCRB) in Q2 2023, closing a stake of 822 shares — an estimated $93.3K sold.

Fox Run Management first reported a position in MCRB in Q3 2016 and held it in 4 quarters. The position peaked at $257K in Q3 2016. 137 funds tracked by Wall St. Rank hold MCRB as of Q2 2023.

  • Fox Run Management reported no remaining Seres Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Fox Run Management sold 822 Seres Therapeutics shares in Q2 2023, an estimated $93.3K.
  • Fox Run Management first reported a position in Seres Therapeutics in Q3 2016 and held it in 4 quarters.
  • Fox Run Management's Seres Therapeutics position peaked at $257K in Q3 2016.
  • 137 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2023.

Based on Fox Run Management's 13F filing for Q2 2023, filed 11 Aug 2023.